Close
  Indian J Med Microbiol
 

Figure 6: Effects of CBTM-E375 on MAPK (p38, ERK1/2, JNK) phosphorylation. HUVECs were pretreated for 12 h with the indicated concentrations of CBTM-E375 and stimulated for 24h with LPS (1 μg/mL), the expression of JNK (a), ERK (b) and p38 (c) were detected as described in materials and methods and representative blots of 3 independent experiments are shown. Data shown represent the mean values of 3 experiments ± standard deviation. #P < 0.05 versus control group; ##P < 0.01 versus control group; *P < 0.05 versus LPS group; **P < 0.01 versus LPS group; was considered to be statistically significant. HUVECs: Human umbilical vein endothelial cells; LPS: Lipopolysaccharide; ERK: Extracellular signal- regulated kinase; JNK: c-Jun-N-terminal kinase; MAPK: Mitogen- activated protein kinase

Figure 6: Effects of CBTM-E375 on MAPK (p38, ERK1/2, JNK) phosphorylation. HUVECs were pretreated for 12 h with the indicated concentrations of CBTM-E375 and stimulated for 24h with LPS (1 μg/mL), the expression of JNK (a), ERK (b) and p38 (c) were detected as described in materials and methods and representative blots of 3 independent experiments are shown. Data shown represent the mean values of 3 experiments ± standard deviation. <sup>#</sup><i>P</i> < 0.05 versus control group; <sup>##</sup><i>P</i> < 0.01 versus control group; *<i>P</i> < 0.05 versus LPS group; **<i>P</i> < 0.01 versus LPS group; was considered to be statistically significant. HUVECs: Human umbilical vein endothelial cells; LPS: Lipopolysaccharide; ERK: Extracellular signal- regulated kinase; JNK: c-Jun-N-terminal kinase; MAPK: Mitogen- activated protein kinase